[Predictive factors of response to targeted therapies: the example of colorectal cancer]

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Epidermal Growth Factor Receptor (EGFR) and Vascular Endothelial Growth Factor (VEGF) are key therapeutic targets in colorectal cancer.
• Targeting strategies include monoclonal antibodies and tyrosine kinase inhibitors for EGFR, and antibodies for VEGF.

Purpose of the Study:

• To review current therapeutic strategies targeting EGFR and VEGF in colorectal cancer.
• To highlight the need for predictive tools to guide the clinical application of these targeted therapies.

Main Methods:

• Literature review of clinical studies and therapeutic approaches for EGFR and VEGF targeting in colorectal cancer.
• Analysis of current clinical applications and emerging data on targeted agents.

Main Results:

• Combination therapy with anti-EGFR antibody cetuximab and irinotecan is a successful strategy in metastatic colorectal cancer.
• Panitumumab shows potential as another anti-EGFR therapeutic option.
• Anti-VEGF antibody bevacizumab combined with 5FU-folinic acid demonstrates encouraging results.

Conclusions:

• Targeted therapies against EGFR and VEGF are advancing in colorectal cancer treatment.
• There is a critical need for clinically validated predictive tools to identify patients who will benefit from these treatments.